XFOR X4 Pharmaceuticals, Inc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501697 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY73.7%
TTM net income YoY15.3%
TTM EPS YoY106.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin68.8%
Operating margin-812.0%
Net margin-813.3%
FCF margin—
EBITDA margin-794.1%
Returns
ROE-80.3%
ROA-40.7%
ROIC (approx.)-134.7%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets40.1%
Debt / equity0.54x
Current ratio13.22x
Interest coverage-9.26x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-2.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.50M | $2.60M |
| Cost of revenue | $5.76M | $797,000 |
| Gross profit | $743,000 | $1.80M |
| R&D expense | $72.72M | $81.64M |
| SG&A expense | $43.52M | $61.52M |
| Operating income | -$86.88M | -$36.40M |
| Interest expense | $8.88M | $8.77M |
| Pretax income | -$79.16M | -$37.14M |
| Income tax | $41,000 | $310,000 |
| Net income | -$79.20M | -$37.45M |
| EBITDA | -$85.61M | -$35.60M |
| EPS (basic) | -1.87 | -5.59 |
| EPS (diluted) | -1.87 | -5.59 |
| Weighted avg. shares (diluted) | 42.29M | 6.70M |
| Balance sheet | ||
| Cash & equivalents | $217.05M | $56.48M |
| Receivables | $573,000 | $1.07M |
| Inventory | $4.48M | $2.82M |
| Current assets | $261.58M | $112.17M |
| PP&E, net | $182,000 | $776,000 |
| Goodwill | $17.35M | $17.35M |
| Intangibles | $9.25M | $10.00M |
| Total assets | $290.46M | $146.45M |
| Current liabilities | $25.76M | $32.88M |
| Long-term debt | $75.00M | $75.00M |
| Total debt | $75.00M | $75.00M |
| Total liabilities | $104.17M | $124.30M |
| Shareholders' equity | $186.29M | $22.15M |
| Net debt | -$142.05M | $18.52M |
| Shares outstanding | 90.91M | 5.70M |
| Cash flow statement | ||
| Operating cash flow | -$85.62M | -$130.90M |
| Capital expenditure | $0 | $326,000 |
| Free cash flow | -$85.62M | -$131.23M |
| Investing cash flow | $8.15M | $66.99M |
| Financing cash flow | $238.63M | $20.29M |
| Depreciation & amortization | $1.28M | $796,000 |
| Stock-based compensation | $4.30M | $8.20M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.